ERCC1 and cancer: Thus, currently targeted therapy regarding ERCC1 has evolved for MUTYH, which is a glycosylase involved in the BER pathway and associated with colorectal cancer, and for MTHFR, interacting with folate synthesis and being prognostic in various cancers [62,131].